Evidence shows that gene therapies for rare diseases display high effectiveness in clinical trials. In fact, orphan gene therapies are 3.5 times more likely to be approved once entering Phase 1 trials than the average drugs included in BIO’s New Clinical Development Success Rates Report. Dive in and learn more about the effectiveness of cell and gene therapies in ARM's latest Sector Snapshot. ➡️ https://lnkd.in/eX2TJiYf
Alliance for Regenerative Medicine
Biotechnology Research
Washington, District of Columbia 24,916 followers
We champion the benefits of engineered cell therapies & genetic medicines for patients, healthcare systems & society.
About us
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and modernize healthcare systems so that patients benefit from durable, potentially curative treatments. As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
- Website
-
http://alliancerm.org
External link for Alliance for Regenerative Medicine
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Washington, District of Columbia
- Type
- Nonprofit
- Founded
- 2009
Locations
-
Primary
1015 18th St NW
Suite 1102
Washington, District of Columbia 20006, US
Employees at Alliance for Regenerative Medicine
Updates
-
The journey to develop therapies for ultra-rare diseases is a testament to the cell and gene therapy sector’s determination to help patients with no other treatment options. Despite challenges and obstacles, a recent article on STAT shows how researchers and companies are developing new models to develop and commercialize gene therapies for conditions with unmet needs. https://lnkd.in/er-dufhz As the voice of the sector, ARM is also engaging with industry leaders on models and methods to address ultra-orphan diseases. You can catch an expert panel on this subject at our upcoming 2024 Meeting on the Mesa. https://lnkd.in/enUunjqK
-
ARM's Cell-Based Immuno-Oncology Workshop is happening next week! Join your colleagues in Philadelphia from September 5-6 to assess the current and future state of adoptive cell therapy and autologous and allogeneic cellular immunotherapies. This event is free for ARM members, and attendees have the option to participate virtually. Register and view the most updated agenda in the link below. ➡ https://lnkd.in/egWwhjpt
-
-
Next week, the IQVIA Institute for Human Data Science will host a multi-stakeholder webinar on 'Strengthening Pathways for Cell and Gene Therapies.' 🗓 September 5 🕙 10:00am - 11:30am EDT Monica Veldman, ARM's Director for Global Regulatory Affairs, will join other industry experts to discuss key challenges, patient access, and the sector's future. Join the webinar here: https://lnkd.in/eXmkyJB6 Full panel: Maria E Santaella, PhD(c), MSN, RN-BC, CPHON VP, Research Strategy National Bleeding Disorders Foundation Mark Trusheim, MS Strategic Director, NEWDIGS Tufts Medical Center Joshi Venugopal, Ph.D. GM and Head of Europe Novartis Gene Therapies Monica Veldman Director, Global Regulatory Affairs Alliance for Regenerative Medicine (ARM) Amritha Jaishankar, Ph.D. Executive Director, Cell and Gene Therapy COE IQVIA Moderator: Murray Aitken Executive Director IQVIA Institute for Human Data Science
-
-
CAR-T cell therapies can help thousands of patients with few other treatment options. For example, approved therapies provide a durable and effective treatment option that can offer hope to those who are in the later stages of cancer. Learn more about the value of these therapies by reading ARM's CAR-T Therapy for Patients and Society Framework: https://lnkd.in/eX2TJiYf
-
-
This week, momentum continued to build for using CAR-T cell therapy as an earlier line of treatment for blood cancers. The European Medicines Agency validated a Marketing Authorization Application for Bristol Myers Squibb's Breyanzi to treat adult patients with R/R follicular lymphoma who received two or more prior lines of therapy. https://lnkd.in/etAQEKJ5 If approved, the milestone would expand the trend of CAR-T cell therapies being authorized as second and third-line treatments for blood cancers. Looking to stay on top of cell and gene therapy sector news? Subscribe to our Sector Vector newsletter for more weekly cell and gene therapy clinical, business, and manufacturing news. 📩 https://lnkd.in/eD7ZNaU
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
news.bms.com
-
Former FDA Commissioner Scott Gottlieb will headline the 2024 Cell & Gene Meeting on the Mesa in Phoenix, AZ, with a fireside chat on October 7! A champion for cell and gene therapies, Dr. Gottlieb played a pivotal role in adapting the agency to the first wave of cell and gene therapy products. Under his leadership, the FDA advanced new frameworks for the modern, safe, and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs, and digital health devices. As commissioner, Dr. Gottlieb predicted the FDA would approve 10-20 cell and gene therapy products per year by 2025. We are delighted to welcome Dr. Gottlieb to Phoenix and look forward to hearing his insights about the future of these transformative medicines. Want to catch his fireside chat? Register for the Meeting on the Mesa: https://lnkd.in/gisXTCii View our sponsorship opportunities: https://lnkd.in/euPJKGvX #CGMesa24
-
A warm welcome to John Aguilar, who joined ARM this week as our Director of Alliance Development. In this role, he will drive strategic engagement for key partnered activities and support the development of coalitions. John has over ten years of experience in healthcare public policy and has held several positions in the non-profit sector. Most recently, he has held public policy positions at the Hispanic Association of Colleges and Universities, the American Academy of Family Physicians, and the American Academy of Otolaryngology-Head and Neck Surgery.
-
-
Which cell and gene therapies have upcoming regulatory decisions? ARM's latest Sector Snapshot on the emerging value of cell and gene therapy highlights what is forthcoming in the clinical pipeline. Dive in today to learn about the upcoming regulatory decisions and check out ARM's latest value frameworks on gene therapy and CAR-T cell therapy. ➡ https://lnkd.in/eX2TJiYf #cellandgenetherapy
-
ARM is #hiring an Associate Director of Finance and Operations to join our Finance Department. We're looking for candidates with experience in financial planning and analysis, payroll processing, and operations with the leadership skills to create a culture of continuous process improvement. Does it sound like a good fit for you? Learn more and apply ➡ https://lnkd.in/ek9q5XF
-